

Michał, Taszner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6432880/publications.pdf>

Version: 2024-02-01

9
papers

39
citations

2258059

3
h-index

1872680

6
g-index

10
all docs

10
docs citations

10
times ranked

100
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	6.2	10
2	Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab. <i>Frontiers in Immunology</i> , 2020, 11, 584509.	4.8	9
3	Mutations resulting in the formation of hyperactive complement convertases support cytotoxic effect of anti-CD20 immunotherapeutics. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 587-598.	4.2	7
4	In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytotoxic Activity of Anticancer Monoclonal Antibodies. <i>Cancers</i> , 2022, 14, 1270.	3.7	5
5	Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group. <i>Journal of Clinical Apheresis</i> , 2018, 33, 249-258.	1.3	3
6	Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma—Polish Lymphoma Research Group real-life analysis. <i>Pharmacological Reports</i> , 2019, 71, 473-477.	3.3	3
7	High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma. <i>Annals of Hematology</i> , 2021, 100, 1755-1767.	1.8	1
8	Ofatumumab with ifosfamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, , .	2.5	1
9	Zastosowanie infuzyjnego schematu chemioterapii DA-EPOCH w leczeniu chłoniaków agresywnych. <i>Acta Haematologica Polonica</i> , 2018, 49, 85-91.	0.3	0